EGTX Egetis Therapeutics AB (publ)
9.060SEK-1.31%Mkt Cap: 402.94M $P/E: —Today
Egetis Therapeutics AB (publ), a pharmaceutical company, engages in the development and commercialization of orphan drugs in Sweden and internationally. It develops Aladote, which is in Phase IIb/III clinical trial for t…
Industry Peers
Biotechnology$127.85BUSDP/E 29.4
$75.86BUSD
$75.69BUSDP/E 18.2
$57.51BUSDP/E 35.1
$55.24BUSDP/E 36.1
$44.29BUSD
$41.63BUSDP/E 17.7
$40.51BUSDP/E 63.9
$33.03BUSDP/E 30.7
$29.40BUSDP/E 38.3
$25.80BUSD
$24.34BUSD
$24.27BUSD
$23.37BUSDP/E 14.7
$21.61BUSDP/E 29.3
$21.69BUSDP/E 27.4
$15.30BUSDP/E 16.1
$14.99BUSDP/E 17.8
$14.47BUSDP/E 18.4
$13.37BUSD
| Headline | Source | Time |
|---|---|---|
Older | ||
 FDA Decision Watch: BMY, EGTX Face Key Decisions This Week As BFRI, SRRK And MIRM Score Early Approvals Bristol Myers Squibb and Egetis await FDA decisions on treatments for heart and rare genetic conditions, while Scholar Rock, Biofrontera and Mirum have already secured regulatory wins ahead of schedule. | ||
Egetis Therapeutics AB (STU:P0F) (Q2 2026) Earnings Call Highlights: FDA Priority Review and US ... Revenue grows 23% year-over-year as company strengthens cash position ahead of potential Q4 2026 US launch of Emcitate. | ||